ClinicalTrials.gg
TerminatedNCT06704906Updated Nov 10, 2026

Adult Patient Outcomes After Spine Surgery With Fibergraft BG Putty/Viper Prime

An observational study in Spondylolisthesis, Lumbar Region, Spinal Trauma With Neurological Deficit and Degeneration of Lumbar Intervertebral Disc, sponsored by University of Pittsburgh. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University of Pittsburgh · Observational

How we know

Why this study was terminated
Investigator left University of Pittsburgh
Updated Nov 10, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
18
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 102 studies in Spondylolisthesis with a site in United States — 14 open to participants now, 18 under way, none of them phase 3. Spondylolisthesis · United States.

Enrollment
34th of 38
18 · median 114
Started
2024
with 4 others
Observational
38 of 102
6 open now
Registered
99th of 102
by date

Among the 102 studies in Spondylolisthesis with a site in United States, this one is the 34th largest by enrollment of the 38 observational ones that give a count, is one of 5 that started in 2024, is one of 38 observational ones, and was the 99th registered.

Spondylolisthesis

227 studies on the registry are indexed under Spondylolisthesis; 43 are open to participants now.

Browse Spondylolisthesis studies →

Open to participants now

14 of the 102 studies in Spondylolisthesis with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Spondylolisthesis studies recruiting now, 11 (41%) set no upper age limit and 8 (30%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Spondylolisthesis with a site in United States, or all of them as a file.
02

Study summary

The Viper Prime/Expedium spine systems are intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of acute and chronic instabilities or deformities of the thoracolumbar and sacral spine. The Fibergraft Bioactive Glass (BG) is engineered to mimic the body's natural bone healing process. While previous studies have compared the use of Viper prime/Expedium spine system in minimally invasive and open surgeries, these studies did not specifically study the clinical and radiographic outcomes of patients who have received these implants in addition to Fibergraft. We aim to recruit patients with degenerative disc disease, spondylolisthesis, trauma, and/or pseudarthrosis who require spine surgery under standard of care and use these implants. We will then follow these patients for a duration of two years to report their clinical and radiographic outcomes to determine fusion, complication rate, and revision surgeries if any.

03

Conditions studied

  • Spondylolisthesis, Lumbar Region
  • Spinal Trauma With Neurological Deficit
  • Degeneration of Lumbar Intervertebral Disc

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with spinal conditions mentioned in inclusion/exclusion criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Have a radiograph-based diagnosis of degenerative disc disease, spondylolisthesis, spinal trauma (i.e., fracture or dislocation), spinal stenosis, or deformity (i.e., scoliosis, kyphosis, and/or lordosis), spinal tumor, or pseudoarthrosis/failed fusion.
  3. Pathology of the thoracolumbar or sacral spine.
  4. Patients requiring fusion of 1-3 levels
  5. Patients receiving the surgery/devices as standard of care prescribed by the treating physician.

Exclusion criteria

Exclusion Criteria:

  1. Patients \< 18 years
  2. Patients with a cervical spine pathology
  3. Patients with spinal tumors
  4. Patients with bone density (DEXA) scores \< 2.0 will be excluded.
  5. Current smokers and patients who quit smoking within 6 weeks prior to presentation will be excluded.
  6. Patients with a > 40kg/m2
  7. Patients requiring fusion for more than 3 levels will be excluded
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
18 participants (actual)
Patient registry
No

Interventions

  • DeviceUse of Viper Prime/Expedium system with Fibergraft BG Putty

    Patients who require spine surgery under standard of care and meet the inclusion and exclusion criteria identified, will be recruited from clinic. Consent for participation in study will be signed at the same time as consent for surgery. All PROMs and scans will be done as standard of care and data will be obtained through chart review for this study.

06

What researchers measure

Primary outcomes

  1. Fusion

    We will assess fusion with regular x-rays and CT scans at 1 and 2-year postoperatively.

    Time frame: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)

Secondary outcomes

  1. Visual Analog Scale (VAS)

    We will have patients fill out validated tools for PROs to assess how the patient is doing postoperatively

    Time frame: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)

  2. Oswestry Disability Index (ODI)

    We will have patients fill out validated tools for PROs to assess how the patient is doing postoperatively

    Time frame: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)

  3. Short form survey-12

    We will have patients fill out validated tools for PROs to assess how the patient is doing postoperatively

    Time frame: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2024 to primary completion in May 2026, 16 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2028 → May 2026 and completion Mar 2029 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2024
First posted
Nov 26, 2024
StartActual
Dec 20, 2024
Primary completionActual
May 2, 2026was Dec 2028
CompletionActual
May 2, 2026was Mar 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Investigator left University of Pittsburgh
changed Nov 10, 2026
Primary completion
Dec 31, 2028→May 2, 2026 (actual)
Nov 10, 2026
Study completion
Mar 30, 2029→May 2, 2026 (actual)
Nov 10, 2026
Enrollment
100 (estimated)→18 (actual)
Nov 10, 2026
Sponsor
Nitin Agarwal→University of Pittsburgh
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Terminated
    Why stopped Investigator left University of Pittsburgh
    Primary completion Dec 31, 2028→May 2, 2026 (now actual)
    Study completion Mar 30, 2029→May 2, 2026 (now actual)
    Enrollment 100 (estimated)→18 (actual)
    Sponsor Nitin Agarwal→University of Pittsburgh
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06704906
Collaborators
DePuy Synthes
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Dec 20, 2024
Primary completion
May 2, 2026
Completion
May 2, 2026
Last update
Nov 10, 2026

Study contacts

Nitin Agarwal, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion